Pharmacogenomics in the clinic.
Pharmacogenomics in the clinic.
复制标题
DOI：
10.1038/nature15817
复制
发表时间：
2015-10-15
期刊：
影响因子：
64.8
通讯作者：
Evans WE
中科院分区：
文献类型：
--
作者：
Relling MV;Evans WE
经过数十年的发现，影响约80种药物的约20个基因的遗传变异已被确定为在临床上可采取行动。额外的体细胞获得的基因组变异指导个体患者“靶向”抗癌药物的选择。目前的努力集中在所需的过程中采取适当行动的药物基因组学的变异性在临床上系统地移动药物基因组学从发现到实施作为一个循证策略，以改善药物的使用，从而提供了一个重要的基石，精准医学。
After decades of discovery, inherited variation in approximately 20 genes affecting about 80 medications has been identified as actionable in the clinic. Additional somatically acquired genomic variants direct the choice of “targeted” anticancer drugs for individual patients. Current efforts that focus on the processes required to appropriately act on pharmacogenomic variability in the clinic are systematically moving pharmacogenomics from discovery to implementation as an evidenced-based strategy for improving the use of medications, thereby providing an important cornerstone for precision medicine.